Scarica l'app Stockscreener
105.69
2.25%
-2.3099
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$108.00
Aprire:
$106.01
Volume 24 ore:
605.53K
Relative Volume:
0.05
Capitalizzazione di mercato:
$183.81B
Reddito:
$46.59B
Utile/perdita netta:
$5.41B
Rapporto P/E:
34.16
EPS:
3.0938
Flusso di cassa netto:
$7.38B
1 W Prestazione:
+4.78%
1M Prestazione:
+16.34%
6M Prestazione:
-3.41%
1 anno Prestazione:
-17.88%
Intervallo 1D:
$105.17
$106.81
Intervallo di 1 settimana:
$101.50
$110.04
Portata 52W:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
105.53 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
348.86 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
86.05 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.01 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.33 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends - TradingView
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
FRAUD AND MANIPULATION—N.D. Ill.: Abbott did not commit securities fraud over tainted baby formula - VitalLaw.com
Abbott (ABT) Lands Exclusive Rights To FDA Approved Blood Based CRC Test - Yahoo Finance
Freenome went public for $300 million, then scored a huge victory with colorectal cancer test - The Business Journals
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth? - Yahoo Finance
Federal Judge Dismisses Abbott Shareholder Lawsuit Over 2022 Infant Formula Recall - Law Commentary
Abbott Labs Shakes Investor Suit Over 2022 Infant Formula Recall - Bloomberg Law News
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott - Fierce Biotech
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Is Abbott Stock Attractive After Its Earnings and Guidance Update? - The Globe and Mail
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - BioSpace
Abbott (ABT) Introduces FDA-Approved SimpleScreen CRC for Colore - GuruFocus
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth - Yahoo Finance
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson - The Globe and Mail
Why Is Abbott Laboratories (NYSE:ABT) a Blue-Chip Stock to Watch? - Kalkine Media
Abbott stock trades steady as investors weigh recent earnings and medical device growth - Ad-hoc-news.de
Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings - Ad-hoc-news.de
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records - Los Angeles Downtown News
Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus - simplywall.st
Abbott defeats shareholder lawsuit over 2022 infant formula recall | Business Information & News | FE - Westlaw Today
Health News Roundup: Abbott Wins Lawsuit, Measles Surge in the US, and More Updates - Devdiscourse
Abbott Beats 'Supersized' Investor Suit Over Formula Recall - Law360
Abbott Wins 7th Circ. Fight Over Baby Formula Warning - Law360
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Abbott Notches Appellate Win in Bellwether Infant Formula Case - news.bloombergtax.com
Abbott defeats shareholder lawsuit over 2022 infant formula recall - Reuters
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher - TradingView
FreeStyle Libre 3 Class Action Lawsuit Alleges Abbott Sold Defective Glucose Monitors - AboutLawsuits.com
Medtech Stocks Have Gotten Slammed. Why Abbott, Danaher, 4 More Are Bargains. - Barron's
Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum - AD HOC NEWS
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Abbott Stock And 2 Dividend Ideas For Retirement Income - simplywall.st
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now? - TradingView
Abbott Faces Spine Stimulator Lawsuit Brought Jointly by 17 Injured Patients - AboutLawsuits.com
Abbott Laboratories (NYSE:ABT) Faces A Profit Test - Kalkine Media
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating - marketscreener.com
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026 - simplywall.st
Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value? - Yahoo Finance
Abbott Laboratories stock holds gains after strong diagnostics and medical devices momentum - Ad-hoc-news.de
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Abbott (NYSE:ABT) Faces A Crucial Valuation Test - Kalkine Media
Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating - marketscreener.com
Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues - insights.citeline.com
Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st
Abbott Laboratories stock steadies as medical devices and diagnostics underpin growth - Ad-hoc-news.de
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Patients sue diagnostics company over data breach - Courthouse News
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories - Yahoo Finance
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.73%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):